Dimerix Limited is an Australian publicly listed, clinical stage, biotechnology company focused on developing new therapies for chronic diseases. Using the company’s proprietary Receptor HIT platform to identify modulators of receptor heteromers, Dimerix has developed a new treatment for chronic kidney disease (CKD). Chronic kidney disease (CKD) is a major global health problem, affecting more than 30 million people in the US alone. This prevalence is expected to increase due to the escalating incidence of cardiovascular disease, obesity and diabetes. CKD is also associated with several life-threatening complications that amplify the effects of the disease and result in significantly worse outcomes for patients. As the disease progresses it can lead to end-stage renal disease (ESRD), where the kidneys fail, resulting in patients requiring dialysis or a kidney transplant. Following a successful Phase 2a study, DMX-200 is about to start two Phase 2 clinical trials for two important subset diseases of CKD: focal segmental glomerulosclerosis (FSGS), for which DMX-200 has Orphan Drug Designation in the USA, and diabetic kidney disease (DKD). DMX-200 works as a treatment for CKD by combining the anti-inflammatory drug propagermanium with the standard of care hypertension treatment irbesartan. see less